Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Walking Exercise
Nicotinamide Riboside (NR)
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring systolic blood pressure (SBP), cardiovascular (CV) disease
Eligibility Criteria
Inclusion Criteria:
- Age 55 years and older
- Daytime average of systolic blood pressure of ≥ 130 mmHg and < 160 mmHg.
- Sedentary lifestyle, defined as < 150 min/wk of moderate physical activity as assessed by the CHAMPS questionnaire.
- Willingness to be randomized to either treatment group
- Willingness to participate in all study procedures
Exclusion Criteria:
- Failure to provide informed consent.
- Pregnant
- Change in blood pressure therapy (type or dose) within the last 3 months- Temporary Exclusion
- Daytime average of systolic blood pressure ≥160 mmHg.
- Regular consumption of nicotinamide riboside supplement
- Current involvement in supervised rehabilitation program
- Absolute contraindication(s) to exercise training according to American College of Sports Medicine guidelines [11]
- Daytime average of systolic blood pressure below 130mm Hg or Diastolic BP ≥ 100mm Hg.
- Peripheral vascular disease; peripheral neuropathy; retinopathy
- Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina;
- Myocardial infarction or stroke within past year
- Significant cognitive impairment, including known dementia diagnosis or a Mini-Mental State Examination exam score < 24
- Progressive, degenerative neurologic disease, e.g., Parkinson's Disease, multiple sclerosis;
- Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement, active inflammatory disease;
- Severe pulmonary disease, requiring steroid therapy or the use of supplemental oxygen;
- Hip fracture, hip or knee replacement, or spinal surgery within past 4 months;
- Other significant co-morbid conditions that would impair ability to participate in the exercise-based intervention
- Simultaneous participation in another intervention trial
Sites / Locations
- UF Institute on Aging
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
NR plus Walking Exercise
Walking Exercise plus Placebo
NR Alone
Arm Description
1,000 mg/day of NR combined with three days/week of supervised, center-based walking exercise (n=18)
1,000 mg/day of Placebo combined with three days/week of supervised, center-based walking exercise (n=18)
1,000 mg/day of NR
Outcomes
Primary Outcome Measures
Change in SBP
SBP will be measured every 20 minutes (min) during the day (from 0700 to 2200 hours), and every 60 min overnight (from 2200 to 0700 hours).
Secondary Outcome Measures
Change in arterial stiffness
Aortic pulse-wave velocity (PWV), commonly measured as carotid to femoral PWV (cfPWV), will be measured using the SphygmoCor XCEL system. Briefly, cfPWV will be determined by recording pressure pulse waves at the carotid and femoral arteries using a high-fidelity micromanometer and calculating the distance between the recording sites divided by the time delay between the carotid and the femoral pulse waves.
Full Information
NCT ID
NCT04112043
First Posted
September 27, 2019
Last Updated
July 13, 2023
Sponsor
University of Florida
Collaborators
National Institute on Aging (NIA)
1. Study Identification
Unique Protocol Identification Number
NCT04112043
Brief Title
Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)
Official Title
Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
July 28, 2020 (Actual)
Primary Completion Date
May 26, 2023 (Actual)
Study Completion Date
May 26, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Florida
Collaborators
National Institute on Aging (NIA)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
More than 80% of older adults have hypertension, with higher prevalence of high systolic blood pressure (SBP) putting them at high risk for cardiovascular (CV) disease and death. Novel compound, nicotinamide riboside may enhance the effects of exercise therapy in hypertensive older adults.
Detailed Description
More than 80% of older adults have hypertension, with a higher prevalence of high systolic blood pressure (SBP) putting them at high risk for cardiovascular (CV) disease and death. Because drug therapy that lowers SBP is associated with side effects such as hypotension, syncope, and kidney dysfunction, there is a great need for effective lifestyle SBP-lowering interventions for the older population that can replace drug therapy. While aerobic exercise is a recommended lifestyle intervention for controlling SBP and preventing CV disease naturally, in older adults it has been shown to be less effective in vascular-tissue remodeling because of arterial stiffness, resulting in less efficient SBP control. Reduced bioavailability of nicotinamide adenine dinucleotide (NAD+), a cofactor for the deacetylase sirtuin1 (SIRT1), may contribute to age-related vascular dysfunction via oxidative stress and reduced nitric oxide (NO). Exercise-induced overexpression of NAD+-dependent SIRT1 improves the bioavailability of NO. Preclinical evidence suggests that poor vascular function improvement in response to exercise in older mice is caused by insufficient NAD+ levels to stimulate SIRT1 activity. Importantly, replenishment of NAD+ levels induced vascular remodeling, improved vascular function, and reduced SBP in mice. An objective of this study, therefore, is to test a combination of aerobic exercise and nicotinamide riboside, a compound that replenishes NAD+ levels, to optimize exercise's SBP-lowering effect in hypertensive older adults. Initial human clinical trials demonstrated that nicotinamide riboside supplementation (1,000 mg/day) was safe and showed a higher potential to reduce SBP and arterial stiffness in participants with elevated SBP. As we have preclinical evidence that combining NAD+ replenishment with exercise is an ideal strategy for improving vascular function, our central hypothesis is that the intervention of aerobic-exercise training combined with nicotinamide riboside supplementation will reduce SBP in hypertensive older adults more effectively than will exercise alone. We will enroll 54 participants ≥ 55 years and older into either: (1) 1,000 mg/day of nicotinamide riboside plus 3 days/week of supervised, center-based walking exercise (n=18), or (2) the same exercise program combined with placebo (n=18), or (3) 1,000 mg/day of nicotinamide riboside alone (n=18). All participants will undergo daytime continuous SBP at baseline, 3 weeks, and 6 weeks, and arterial-stiffness measurements by pulse-wave velocity at baseline and at 6 weeks. Elevated SBP will be determined as daytime average equal to or above 130 mmHg, measured by the 24-hour blood-pressure device. To our knowledge, this study will be the first attempt to enhance exercise therapy with nicotinamide riboside in hypertensive older adults. We believe that nicotinamide riboside is "the missing piece of the puzzle" in improving vascular remodeling and SBP management in older adults. Preliminary evidence from this pilot study may support a full-scale Phase III clinical trial in hypertensive older adults. The ultimate goal of this line of research is to find adjuvant strategies to improve the exercise's SBP-lowering effects in older adults.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
systolic blood pressure (SBP), cardiovascular (CV) disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
49 (Actual)
8. Arms, Groups, and Interventions
Arm Title
NR plus Walking Exercise
Arm Type
Active Comparator
Arm Description
1,000 mg/day of NR combined with three days/week of supervised, center-based walking exercise (n=18)
Arm Title
Walking Exercise plus Placebo
Arm Type
Active Comparator
Arm Description
1,000 mg/day of Placebo combined with three days/week of supervised, center-based walking exercise (n=18)
Arm Title
NR Alone
Arm Type
Active Comparator
Arm Description
1,000 mg/day of NR
Intervention Type
Behavioral
Intervention Name(s)
Walking Exercise
Intervention Description
Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.
Intervention Type
Drug
Intervention Name(s)
Nicotinamide Riboside (NR)
Intervention Description
Participants randomized to this intervention will receive 1,000 mg/day of NR.
Primary Outcome Measure Information:
Title
Change in SBP
Description
SBP will be measured every 20 minutes (min) during the day (from 0700 to 2200 hours), and every 60 min overnight (from 2200 to 0700 hours).
Time Frame
Baseline; Week 6
Secondary Outcome Measure Information:
Title
Change in arterial stiffness
Description
Aortic pulse-wave velocity (PWV), commonly measured as carotid to femoral PWV (cfPWV), will be measured using the SphygmoCor XCEL system. Briefly, cfPWV will be determined by recording pressure pulse waves at the carotid and femoral arteries using a high-fidelity micromanometer and calculating the distance between the recording sites divided by the time delay between the carotid and the femoral pulse waves.
Time Frame
Baseline; Week 3; Week 6
10. Eligibility
Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
105 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 55 years and older
Daytime average of systolic blood pressure of ≥ 130 mmHg and < 160 mmHg.
Sedentary lifestyle, defined as < 150 min/wk of moderate physical activity as assessed by the CHAMPS questionnaire.
Willingness to be randomized to either treatment group
Willingness to participate in all study procedures
Exclusion Criteria:
Failure to provide informed consent.
Pregnant
Change in blood pressure therapy (type or dose) within the last 3 months- Temporary Exclusion
Daytime average of systolic blood pressure ≥160 mmHg.
Regular consumption of nicotinamide riboside supplement
Current involvement in supervised rehabilitation program
Absolute contraindication(s) to exercise training according to American College of Sports Medicine guidelines [11]
Daytime average of systolic blood pressure below 130mm Hg or Diastolic BP ≥ 100mm Hg.
Peripheral vascular disease; peripheral neuropathy; retinopathy
Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina;
Myocardial infarction or stroke within past year
Significant cognitive impairment, including known dementia diagnosis or a Mini-Mental State Examination exam score < 24
Progressive, degenerative neurologic disease, e.g., Parkinson's Disease, multiple sclerosis;
Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement, active inflammatory disease;
Severe pulmonary disease, requiring steroid therapy or the use of supplemental oxygen;
Hip fracture, hip or knee replacement, or spinal surgery within past 4 months;
Other significant co-morbid conditions that would impair ability to participate in the exercise-based intervention
Simultaneous participation in another intervention trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Mankowski, PhD
Organizational Affiliation
University of Florida
Official's Role
Principal Investigator
Facility Information:
Facility Name
UF Institute on Aging
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32611
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)
We'll reach out to this number within 24 hrs